Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
According to the NCI, in 2015 there were an estimated 124,733 people living with multiple myeloma in the United States. According to the Myeloma Beacon article linked and excerpted below, almost half of those MM survivors are living with some degree of cognitive dysfunction aka chemo-brain.
After careful reading, you can see the article below focusing on several central issues to our lives as MMers. These issues are central to what newly diagnosed MMers must consider before undergoing induction therapy and again if he/she is considering an autologous stem cell transplant (ASCT).
Newly diagnosed MMers can take the info below into account when considering your therapy plan.
The central issues for brain health for newly diagnosed MMers are:
The take-away for the article is 1) can newly diagnosed MMer prevent chemo-brain and 2) can MMers heal our chemo-brain? I believe in those integrative therapies shown to reduce chemo toxicity. Further, I follow chemo-brain healing regimen daily, weekly and monthly.
I have lived with multiple myeloma since my original diagnosis in 1994. I have lived in complete remission since April of 1999. If you would like to learn more about healing your chemo-brain and/or managing your multiple myeloma, scroll down the page, post a question or a comment and I will reply ASAP.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
“Results from a recent study indicate that many myeloma patients are likely to suffer impaired cognitive function after their initial multiple myeloma therapy, and stem cell transplantation often causes further impairment.
Nearly half of the patients in the study had cognitive impairment, often referred to as ‘chemo-brain,’ after receiving initial anti-myeloma therapy. Half of the patients experienced further impairment of cognitive function at one month and again at three months following autologous (own) stem cell transplantation.
The study authors explain that the most common signs of cognitive impairment were problems with learning, memory, and coordination.
In addition, they note that older patients, minorities, those with more advanced disease, more induction cycles, or impaired cognitive function following induction therapy were at greater risk for further cognitive impairment following stem cell transplantation...
Based on their results, the investigators suggest that patients who undergo autologous stem cell transplantation, particularly those who expect to resume work that involves high cognitive demand, be made aware of the risk of cognitive impairment following transplantation and offered counseling or support…
Following induction therapy and prior to autologous stem cell transplantation, 47 percent of the patients already showed signs of cognitive impairment, with learning/memory and executive function being the most compromised. Executive function refers to the ability to plan, organize, strategize, execute, and manage time.
In particular, older patients were found to be more likely to have psychomotor speed issues. Psychomotor function refers to simple actions that involve communication between the brain and other body parts, such as throwing a ball or driving a car…
Of the 41 patients who were available to be assessed one month following transplantation, 49 percent experienced worse cognitive function after transplantation compared to before transplantation. Specifically, 20 percent of patients declined on one, 10 percent on two, and 20 percent on three measures of cognitive function.
The investigators note that the most common cognitive issues a month after transplantation were learning/memory problems (22 percent to 29 percent of the patients) and motor function (15 percent of the patients).
Of the 29 patients who were available to be assessed three months following transplantation, 48 percent showed cognitive decline compared to their cognitive function one month after transplantation. Specifically, 31 percent of the patients declined on one, 14 percent on two, and 4 percent on three measures of cognitive function.
Similar to the previous two assessments, learning/memory problems (18 percent of the patients) and psychomotor speed (21 percent of the patients) were the most commonly affected functions.
Age, education, disease stage, number of induction cycles, and cognitive impairment prior to stem cell transplantation were all associated with impaired cognitive function three months after transplantation.
The researchers note that only 25 percent of patients displayed stable or improving performance on all cognitive measures throughout the study.
For more information, please refer to the study in the journal Cancer (abstract).”